Profile
ALVOW ZTS HLN TAK TEVA VTRS
Company Name Alvotech Zoetis Inc. Haleon plc Takeda Pharmaceutical Company Limited Teva Pharmaceutical Industries Limited Viatris Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic Drug Manufacturers - Specialty & Generic
Market Cap $3.62B $79.26B $42.82B $42.13B $18.71B $15.67B
Employees 1.00K 14.10K 25.41K 49.28K 37.00K 32.00K
CEO Mr. Robert Wessman Ms. Kristin C. Peck Mr. Brian James McNamara Mr. Christophe Weber Mr. Richard D. Francis Mr. Scott Andrew Smith Ph.D.
Ratings
ALVOW ZTS HLN TAK TEVA VTRS
Quant Rating Score 2 3 3 3 1 3
Quant Rating Sell Neutral Neutral Neutral Strong Sell Neutral
Trading
ALVOW ZTS HLN TAK TEVA VTRS
Last Close $3.4 $175.67 $9.48 $13.29 $17.03 $13.13
High 52 $5.8 $199.94 $10.69 $15.08 $18.96 $13.53
Low 52 $2.21 $145.54 $8.01 $12.6 $10.44 $10.05
Price vs. 52 Week High -41.38 % -12.14 % -11.32 % -11.87 % -10.18 % -2.96 %
Price vs. 52 Week Low 53.85 % 20.7 % 18.35 % 5.48 % 63.12 % 30.65 %
Total Return
ALVOW ZTS HLN TAK TEVA VTRS
1 Month Return 21.43 % -7.27 % -5.01 % -6.08 % -6.33 % 13.48 %
3 Month Return 13.33 % -3.95 % -3.95 % -11.04 % -6.07 % 12.03 %
6 Month Return 9.68 % 1.67 % 11.27 % 0.68 % 2.65 % 19.8 %
9 Month Return -21.84 % -6.75 % 13.81 % -9.84 % 31 % -0.98 %
YTD Return 36 % -10.99 % 15.19 % -6.87 % 63.12 % 21.24 %
1 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
ALVOW ZTS HLN TAK TEVA VTRS
Dividend Yield Percentage (TTM) - 0.98 % 2.11 % 4.77 % - 3.66 %
Dividend Paid and Capex Coverage Ration (TTM) -9.45 % 2.1 % - 1.29 % 5.06 % 2.39 %
Dividend Per Share (TTM) - 1.73 % 0.16 % 0.63 % - 0.48 %
Payout Ratio (TTM) - 31.44 % - 101.62 % - -65.15 %
Growth
ALVOW ZTS HLN TAK TEVA VTRS
Asset Growth 14.68 % -4.28 % -2.18 % 8.25 % -1.2 % -4.67 %
Gross Profit Growth -466.65 % 3.7 % 5.85 % -16.6 % 9.64 % -0.9 %
Revenue Growth 10.12 % 5.74 % 4.09 % 5.87 % 6.16 % -5.14 %
Revenue 3 Year -81.13 % 31.98 % 13.9 % 33.13 % -6.92 % -35.32 %
Revenue 5 Year 207.13 % 53.64 % 32.87 % 149.89 % -23.33 % -41.73 %
Revenue 10 Year 207.13 % 103.1 % 32.87 % 154.38 % -40.82 % -26.57 %
EBIT Growth -2.43 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Net Income Growth -7.43 % 10.88 % -1.04 % -54.56 % 76.24 % -97.37 %
Net Income 3 Yeari Growth Per Share 55.38 % 47.55 % -8.67 % -61.74 % 86.29 % 104.09 %
Net Income 5 Yeari Growth Per Share -181.85 % 71.94 % 59.66 % 62.27 % 76.28 % -93.3 %
Net Income 10 Yeari Growth Per Share -181.85 % 404.24 % 59.66 % 36.33 % -133.42 % -97.12 %
Operating Income Growth -2.43 % 6.27 % 37.26 % 7.34 % -84.52 % -52.55 %
Operating Cash Flow Growth (CFG) 0.07 % 23.06 % -16.48 % -34.47 % -13.96 % -5.18 %
Operating 3 Year CFG 42.22 % 14.12 % 22.08 % -36.76 % 10.09 % 13.84 %
Operating 5 Year CFG -277.99 % 37.69 % 118.54 % 139.61 % -48.98 % -48.37 %
Operating 10 Year CFG -277.99 % 274.61 % 118.54 % 335.67 % -67.94 % -16.8 %
EPS Growth 6.54 % 12.64 % - -54.92 % 76.42 % -97.08 %
EPS Diluted Growth 6.54 % 12.92 % - -54.86 % 76.42 % -97.08 %
Book Value Per Share -43.74 % 15.25 % 1.35 % 13.54 % -7.25 % -1.92 %
Share Holder 3 Year Equity Growth Per Share 85.21 % 36.7 % -36.6 % 40.38 % -26.74 % -55.34 %
Share Holder 5 Year Equity Growth Per Share - 139.55 % -39.41 % 73.27 % -53.44 % -27.35 %
Share Holder 10 Year Equity Growth Per Share - 476.36 % -39.41 % 197.1 % -74.76 % 128.81 %
Dividend Per Share Growth - 15.15 % -85.58 % 1.95 % - -0.06 %
Dividend 3 Year Growth Per Share - 87.76 % -83.69 % 1.19 % - -
Dividend 5 Year Growth Per Share - 198.29 % -66.42 % 146.94 % -100 % -
Dividend 10 Year Growth Per Share - 665.58 % -66.42 % 103.93 % -100 % -
Debt Growth 33.58 % -15.91 % -9.43 % 24.67 % -6.53 % -5.93 %
Free Cash Flow Growth 0.76 % 22.25 % -20.06 % -53.54 % -19.19 % -7.35 %
Updated On 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Mar 2024 31 Dec 2023 31 Dec 2023
Profitability
ALVOW ZTS HLN TAK TEVA VTRS
Gross Profit Margin TTM 44 % 68.87 % 59.91 % 62.47 % 49.87 % 40.26 %
Return on Assets TTM -57.87 % 16.93 % 3.26 % 1.99 % -2.38 % -1.97 %
Return on Equity TTM 86.54 % 47.99 % 6.54 % 4.04 % -14.58 % -4.43 %
Return on Capital Employed TTM 109.54 % 26.64 % 7.25 % 5.27 % 7.66 % -0.71 %
Net Income Per EBT TTM 93.31 % 79.65 % 65.38 % 109.03 % 175.89 % 92.81 %
EBT Per Ebit TTM 451.51 % 90.51 % 82.66 % 41.38 % -26.34 % 359.67 %
EBIT Per Revenue TTM -51.98 % 36.83 % 17.88 % 14.14 % 12.76 % -1.76 %
Cash Flow To Debt Ratio TTM -29.38 % 44.8 % - 17.01 % 13 % 13.05 %
Receivables Turnover TTM 1.82 6.49 5.27 6.3 4.85 3.81
Payables Turnover TTM 2.7 7.05 1.25 4.13 3.55 7.23
Inventory Turnover TTM 1.64 1.18 3.09 1.41 2.13 2.2
Fixed Asset Turnover TTM 74.77 % 259.93 % 604.62 % 240.84 % 278.05 % 561.67 %
Asset Turnover TTM 26.43 % 63.75 % 33.71 % 31.2 % 40.19 % 33.6 %
Operating Cash Flow Per Share TTM -1.2 6.5 - 545.34 2.18 1.93
Free Cash Flow Per Share TTM -1.33 5.1 - 309.43 1.75 1.6
Cash Per Share TTM 4.23 % 378.45 % 5.72 % 57513.46 % 292.94 % 157.41 %
Operating Cash Flow Sales Ratio TTM -109.85 % 32.18 % - 18.9 % 14.71 % 15.29 %
Free Cash Flow Operating Cash Flow Ratio TTM 110.58 % 78.37 % - 56.74 % 80.23 % 83.19 %
Cash Flow Coverage Ratios TTM -29.38 % 44.8 % - 17.01 % 13 % 13.05 %
Price To Free Cash Flows Ratio TTM -10.82 34.34 - 13.34 9.45 8.19
Price To Operating Cash Flows Ratio TTM -10.27 27.02 - 3.76 7.82 6.81
Price Cash Flow Ratio TTM -10.27 27.02 - 3.76 7.82 6.81
Income Statement (TTM)
ALVOW ZTS HLN TAK TEVA VTRS
Revenue $0.09B $8.54B $11.3B $4263.76B $15.85B $15.43B
Gross Profit $-0.07B $5.83B $6.96B $2321.31B $7.65B $6.44B
Gross Profit Ratio -75.93% 68.28% 61.6% 54.44% 48.25% 41.74%
EBITDA $-0.48B $3.69B $2.35B $900.33B $4.33B $3.52B
Net Income $-0.55B $2.34B $1.05B $144.07B $-0.56B $0.05B
EPS Diluted -2.43 5.07 0.11 91.16 -0.5 0.05
Balance Sheet (MRQ)
ALVOW ZTS HLN TAK TEVA VTRS
Long Term Debt $1.03B $6.75B $8.95B $5029.93B $18.48B $16.35B
Total Liabilities $1.88B $9.3B $17.33B $7834.79B $35.35B $27.22B
Total Equity $-0.93B $4.99B $16.73B $7274.01B $8.13B $20.47B
Total Investments $0.02B $0.02B $0.07B $683.22B $0.01B $1.33B
Total Debt $1.08B $6.76B $9.46B $5463.39B $20.15B $18.37B
Total Assets $0.95B $14.29B $34.06B $15108.79B $43.48B $47.69B
Cash Flow Statement (TTM)
ALVOW ZTS HLN TAK TEVA VTRS
Net Income $-0.55B $2.34B $1.05B $144.07B $-0.62B $0.05B
Inventory $-0.01B $-0.36B $-0.13B $-115.74B $0B $-0.61B
Dividends Paid $0B $-0.69B $-0.39B $-287.19B $0B $-0.58B
Operating Cash Flow $-0.31B $2.35B $1.72B $640.32B $1.37B $2.8B
Capital Expenditure $-0.05B $-0.73B $-0.34B $-480.73B $-0.53B $-0.47B
Related Stocks
Ticker Name Price
ACB Aurora Cannabis Inc. 4.24
ACOR Acorda Therapeutics, Inc. 0.661
ACRX AcelRx Pharmaceuticals, Inc. 0.86
ADMP Adamis Pharmaceuticals Corporation 0.775
ADMS Adamas Pharmaceuticals, Inc. 8.22
AERI Aerie Pharmaceuticals, Inc. 15.25
AGRX Agile Therapeutics, Inc. 1.51
AKAN Akanda Corp. 1.37
ALIM Alimera Sciences, Inc. 5.54
ALVO Alvotech 12.42
AMPH Amphastar Pharmaceuticals, Inc. 44.09
AMRX Amneal Pharmaceuticals, Inc. 8.41
AMYT Amryt Pharma plc 14.7
ANIP ANI Pharmaceuticals, Inc. 55.1
AQST Aquestive Therapeutics, Inc. 4.735
ASRT Assertio Holdings, Inc. 0.95
ATNX Athenex, Inc. 0.2031
AVDL Avadel Pharmaceuticals plc 10.75
AYTU Aytu BioPharma, Inc. 1.49
BDSI BioDelivery Sciences International, Inc. 5.59
Unlock